Oncotarget

Corrections:

Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)

Hye Ryun Kim, Joung Soon Jang, Jong-Mu Sun, Myung-Ju Ahn, Dong-Wan Kim, Inkyung Jung, Ki Hyeong Lee, Joo-Hang Kim, Dae Ho Lee, Sang-We Kim _ and Byoung Chul Cho

PDF  |  How to cite

Oncotarget. 2017; 8:55766-55766. https://doi.org/10.18632/oncotarget.20268

Metrics: PDF 2049 views  |   ?  

Present: The current funding information is incomplete.

Corrected: The complete funding information is given below.

Original article: Oncotarget. 2017; 8:15943-51. DOI:https://doi.org/10.18632/oncotarget.13056.

FUNDING

This study was supported partly by Astra Zeneca Korea Ltd. This study was supported in part by a grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI12C1440, B. C. Cho), a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI13C1948 to H.R. Kim) and a faculty research grant of Yonsei University College of Medicine for 2012(6-2012-0134, B.C. Cho.).


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20268